Motility Pharmacology: Prokinetics and Antiemetics

The chemoreceptor trigger zone is located in the area postrema on the floor of the fourth ventricle. Its defining feature is that it lies outside the blood-brain barrier, allowing circulating emetogenic substances — chemotherapy drugs, opioids, uremic toxins, digoxin — to reach and activate it directly without penetrating the brain. The chemoreceptor trigger zone is densely populated with dopamine D2 receptors, serotonin 5-HT3 receptors, and neurokinin 1 receptors, making it the primary pharmacological target for antiemetics used in chemotherapy-induced and postoperative nausea and vomiting. Activated chemoreceptor trigger zone neurons send signals to the vomiting center in the medullary dorsal vagal complex.

The vomiting center in the nucleus tractus solitarius receives convergent input from four sources. First, the chemoreceptor trigger zone signals blood-borne emetogenic stimuli. Second, vagal afferents from the gastrointestinal tract carry signals generated by enterochromaffin cell serotonin release in response to mucosal injury, distension, or cytotoxic drugs — this peripheral serotonin pathway is the dominant mechanism of acute chemotherapy-induced nausea and vomiting within the first 24 hours. Third, the vestibular nuclei transmit signals from the inner ear, which is why motion sickness and labyrinthine disorders cause nausea. Fourth, higher cortical centers mediate anticipatory nausea and anxiety-driven emesis.

Understanding which input dominates in a given clinical situation is the key to selecting the right antiemetic class. Chemotherapy-induced nausea and vomiting requires blockade of the chemoreceptor trigger zone and vagal serotonin pathway. Motion sickness requires vestibular pathway blockade. Opioid-induced nausea requires chemoreceptor trigger zone dopamine D2 receptor blockade.

Serotonin 5-HT3 receptor antagonists block serotonin receptors on vagal afferent terminals in the gut wall and on neurons in the nucleus tractus solitarius, interrupting the peripheral serotonin-mediated afferent signal that drives acute chemotherapy-induced nausea and vomiting within the first 24 hours. They are also highly effective for postoperative nausea and vomiting. Ondansetron is the prototype and the most widely used; granisetron, dolasetron, and palonosetron are later agents. Palonosetron has a substantially longer half-life and higher receptor affinity than first-generation agents, with superior efficacy for delayed chemotherapy-induced nausea and vomiting compared to ondansetron.

The key adverse effect is QTc interval prolongation through cardiac potassium channel blockade. The FDA recommends against single intravenous doses of ondansetron greater than 32 milligrams. The risk is greatest in patients with pre-existing QTc prolongation, hypokalemia, hypomagnesemia, or concurrent QTc-prolonging drugs. Palonosetron has minimal cardiac channel affinity and does not cause clinically significant QTc prolongation. Constipation and headache are common non-cardiac adverse effects across the class.

Substance P acting on neurokinin 1 receptors in the central nervous system mediates the delayed phase of chemotherapy-induced nausea and vomiting — the nausea that peaks at 48 to 72 hours post-chemotherapy and persists through day 5. Neurokinin 1 receptor antagonists block this pathway. Aprepitant is given orally for 3 days starting on the day of chemotherapy; fosaprepitant is the intravenous prodrug. Netupitant is available in a fixed-dose combination with palonosetron, conveniently combining both drug classes in a single capsule.

Aprepitant is a moderate inhibitor of cytochrome P450 3A4 and also induces cytochrome P450 2C9. The cytochrome P450 3A4 inhibition increases dexamethasone exposure substantially; when dexamethasone is used as part of a chemotherapy-induced nausea and vomiting prophylaxis regimen with aprepitant, the dexamethasone dose is typically reduced by approximately 50 percent. The cytochrome P450 2C9 induction reduces warfarin concentrations; the international normalized ratio should be monitored in anticoagulated patients receiving aprepitant.

In diabetic gastroparesis, chronic hyperglycemia damages the interstitial cells of Cajal that generate gastric pacemaker activity and injures enteric neurons and the vagus nerve through autonomic neuropathy. The result is loss of coordinated antral contractility and pyloric relaxation. Idiopathic gastroparesis is the most common form overall; post-surgical gastroparesis follows vagotomy or fundoplication. Diagnosis requires gastric emptying scintigraphy with retention of greater than 10 percent of a standardized solid meal at 4 hours after ingestion, with mechanical obstruction excluded.

Metoclopramide 5 to 10 milligrams three to four times daily before meals is the only FDA-approved drug for gastroparesis in the United States and is first-line despite its tardive dyskinesia risk. Use the lowest effective dose, document the start date, and plan for a maximum 12-week course. For acute exacerbations or when oral therapy fails, intravenous metoclopramide is standard inpatient management. Low-dose erythromycin is a useful second-line agent for acute crises but loses efficacy within weeks of continuous use from tachyphylaxis. Domperidone, available through FDA expanded access for patients who cannot tolerate metoclopramide and have a normal baseline QTc, avoids extrapyramidal adverse effects but requires cardiac monitoring.

Non-pharmacological measures are integral: small frequent low-fat low-fiber meals, tight glycemic control in diabetic patients (acute hyperglycemia itself inhibits gastric motility), and in refractory cases gastric electrical stimulation device therapy for symptom relief.